News | October 18, 2010

First Canadian Hospital Implants Left Ventricular Assist System

October 18, 2010 – Toronto General Hospital is the first Canadian medical center to implant a left-ventricular assist system (LVAS) as part of a study for patients awaiting a heart transplant. The Peter Munk Cardiac Centre used the DuraHeart LVAS, by Terumo Heart, as part of the SUSTAIN BTT study.

The DuraHeart LVAS is designed to aid the pumping action of the heart in order to circulate blood throughout the body, and is for use in patients with end-stage heart failure. Due to the scarcity of donor organs, patients can be on the waiting list for months until a suitable donor becomes available.

“We are pleased to be the first center in Canada to bring this state-of-the-art technology to our heart failure patients,” said Vivek Rao, M.D., surgical director of the heart transplant program at The Peter Munk Cardiac Centre, and DuraHeart LVAS clinical investigator. “We look forward to being part of the landmark SUSTAIN trial evaluating the DuraHeart LVAS, which we believe is one of the most advanced left-ventricular assist devices currently available.”

The system incorporates a centrifugal flow rotary pump with a magnetically levitated impeller. The pump features three position sensors and electromagnetic coils that suspend the impeller inside the pump chamber without a single point of contact. The impeller’s active magnetic levitation is designed to eliminate friction by allowing a wide gap between blood contacting surfaces, enabling blood to flow through the pump unimpeded in a smooth, non-turbulent fashion.

The study was granted unconditional approval in early 2010 by the U.S. Food & Drug Administration (FDA). The DuraHeart LVAS already carries a CE Mark and is currently available for sale in European countries. The company has recently completed clinical trial enrollment for this device in Japan, and has submitted its Destination Therapy (DT) Investigational Device Exemption to the FDA, which is a first step in the process of obtaining approval to begin its DuraHeart DT Clinical Trial in the United States.

For more information: www.terumoheart.com

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...